The TAGLN2 (Transgelin-2) antibody is a crucial tool for studying the TAGLN2 protein, a member of the calponin-transgelin family involved in cytoskeletal reorganization and cell motility. TAGLN2. also known as SM22α homolog, is expressed in various cell types, including smooth muscle cells, fibroblasts, and immune cells. It regulates actin dynamics by binding to actin filaments, influencing cell adhesion, migration, and contractility. Research highlights its role in cancer progression, where its upregulation correlates with tumor metastasis, epithelial-mesenchymal transition (EMT), and poor prognosis in cancers like glioblastoma, breast, and colorectal cancer.
TAGLN2 antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein expression and localization. They help elucidate TAGLN2's interaction with signaling pathways (e.g., TGF-β, Wnt) and its impact on tumor microenvironments. Recent studies also implicate TAGLN2 in immune regulation, particularly in T-cell activation and macrophage polarization, suggesting therapeutic potential in autoimmune diseases and immunotherapy.
Commercial TAGLN2 antibodies are typically validated for specificity and sensitivity, though variability in isoforms and post-translational modifications necessitates careful experimental optimization. Ongoing research aims to clarify its dual roles in pro- and anti-tumorigenic contexts, underscoring its value as a biomarker and therapeutic target.